Facial Plast Surg 2013; 29(05): 373-383
DOI: 10.1055/s-0033-1353377
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chemoprevention of Nonmelanoma Skin Cancer

Razieh Soltani-Arabshahi
1   Department of Dermatology, University of Utah, Salt Lake City, Utah
,
Payam Tristani-Firouzi
1   Department of Dermatology, University of Utah, Salt Lake City, Utah
› Author Affiliations
Further Information

Publication History

Publication Date:
13 September 2013 (online)

Abstract

Chemoprevention is suitable for patients who are at high risk of development of numerous or invasive nonmelanoma skin cancers (NMSCs). Various substances have been studied as potential chemopreventive agents for NMSC. Oral retinoids have been proven to be effective in the suppression of new squamous cell carcinoma (SCC) development. Patients need to stay on oral retinoids as long as chemoprevention is needed with careful monitoring of the dose and side effects. Topical retinoids are not effective in prevention of NMSC. In organ transplant patients with aggressive or numerous skin cancers, decrease in the immunosuppression or switch to mammalian target of rapamycin inhibitors (sirolimus or everolimus) can be considered. Field therapy for areas of severe actinic damage with photodynamic therapy, imiquimod, 5-fluorouracil, ingenol mebutate, or diclofenac sodium may theoretically decrease the risk of SCC through treatment of precancerous changes. However, there is limited data regarding efficacy of these agents in chemoprevention of NMSC. Epidemiologic studies suggest a protective role for nonsteroidal anti-inflammatory agents in development of NMSC. Limited data support chemopreventive effect of difluoromethylornithine and T4 endonuclease V for actinic keratoses and basal cell carcinoma. Amongst dietary factors, low-fat diet, limonene from citrus fruit peel, and caffeine may protect against NMSC.

 
  • References

  • 1 Rigel DS, Friedman RJ, Kopf AW. Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5. J Am Acad Dermatol 1996; 35 (6) 1012-1013
  • 2 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5) 277-300
  • 3 Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 (Suppl. 61) 1-6
  • 4 Rowe DE, Carroll RJ, Day Jr CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15 (3) 315-328
  • 5 Rowe DE, Carroll RJ, Day Jr CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26 (6) 976-990
  • 6 Chuang TY, Popescu NA, Su WP, Chute CG. Squamous cell carcinoma. A population-based incidence study in Rochester, Minn. Arch Dermatol 1990; 126 (2) 185-188
  • 7 Lewis KG, Weinstock MA. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol 2007; 127 (10) 2323-2327
  • 8 Chen JG, Fleischer Jr AB, Smith ED , et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 2001; 27 (12) 1035-1038
  • 9 Green AE, Hedinger RA. Models relating ultraviolet light and non-melanoma skin cancer incidence. Photochem Photobiol 1978; 28 (2) 283-291
  • 10 Fears TR, Scotto J. Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest 1983; 1 (2) 119-126
  • 11 Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65 (2) 253-261 , quiz 262
  • 12 Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients—where do we stand today?. Am J Transplant 2008; 8 (11) 2192-2198
  • 13 Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer 2004; 4 (1) 23-35
  • 14 Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36 (7 PT 2) 2699-2702
  • 15 Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006; 32 (4) 562-568
  • 16 Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65 (2) 263-279 , quiz 280
  • 17 Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sørensen HT. Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol 2010; 90 (5) 474-479
  • 18 Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010; 10 (8) 1889-1896
  • 19 Euvrard S, Kanitakis J, Decullier E , et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81 (8) 1093-1100
  • 20 Mehrany K, Weenig RH, Lee KK, Pittelkow MR, Otley CC. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol 2005; 53 (6) 1067-1071
  • 21 Otley CC, Cherikh WS, Salasche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol 2005; 53 (5) 783-790
  • 22 Clarke N, Germain P, Altucci L, Gronemeyer H. Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 2004; 6 (25) 1-23
  • 23 Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278 (5340) 1073-1077
  • 24 Peck GL, Gross EG, Butkus D, DiGiovanna JJ. Chemoprevention of basal cell carcinoma with isotretinoin. J Am Acad Dermatol 1982; 6 (4 Pt 2, Suppl): 815-823
  • 25 Peck GL, DiGiovanna JJ, Sarnoff DS , et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988; 19 (1 Pt 2) 176-185
  • 26 Peck GL. Long-term retinoid therapy is needed for maintenance of cancer chemopreventive effect. Dermatologica 1987; 175 (Suppl. 01) 138-144
  • 27 Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999; 341 (23) 1767-1768
  • 28 Bardazzi F, Bianchi F, Parente G, Guareschi E, Landi C. A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ. J Am Acad Dermatol 2005; 52 (6) 1102-1104
  • 29 Smit JV, Cox S, Blokx WA, van de Kerhof PC, de Jongh GJ, de Jong EM. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol 2002; 147 (4) 816-818
  • 30 Weinstock MA, Bingham SF, Digiovanna JJ , et al; Veterans Affairs Topical Tretinoin Chemoprevention Trial Group. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012; 132 (6) 1583-1590
  • 31 Otley CC, Berg D, Ulrich C , et al; REDUCTION OF IMMUNOSUPPRESSION TASK FORCE OF THE INTERNATIONAL TRANSPLANT SKIN CANCER COLLABORATIVE and THE SKIN CARE IN ORGAN TRANSPLANT PATIENTS EUROPE. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006; 154 (3) 395-400
  • 32 Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80 (7) 883-889
  • 33 Yakupoglu YK, Buell JF, Woodle S, Kahan BD. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 2006; 38 (2) 358-361
  • 34 de Fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007; 22 (Suppl. 01) i23-i26
  • 35 Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007; 67 (3) 369-391
  • 36 Varma S, Wilson H, Kurwa HA , et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001; 144 (3) 567-574
  • 37 Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 2010; 162 (1) 171-175
  • 38 Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86 (1) 25-28
  • 39 de Graaf YG, Kennedy C, Wolterbeek R, Collen AF, Willemze R, Bouwes Bavinck JN. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126 (3) 569-574
  • 40 Willey A, Mehta S, Lee PK. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg 2010; 36 (5) 652-658
  • 41 Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis—a systematic review of randomized controlled trials. Int J Dermatol 2009; 48 (5) 453-463
  • 42 Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011; 165 (5) 1101-1108
  • 43 Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24 (6) 990-1000
  • 44 Schön MP, Schön M. Imiquimod: mode of action. Br J Dermatol 2007; 157 (Suppl. 02) 8-13
  • 45 Korman N, Moy R, Ling M , et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141 (4) 467-473
  • 46 Patel GK, Goodwin R, Chawla M , et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54 (6) 1025-1032
  • 47 Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133 (10) 1239-1242
  • 48 Martin GM, Stockfleth E. Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety. J Drugs Dermatol 2012; 11 (5) 600-608
  • 49 Ulrich C, Johannsen A, Röwert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010; 20 (4) 482-488
  • 50 Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366 (11) 1010-1019
  • 51 An KP, Athar M, Tang X , et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002; 76 (1) 73-80
  • 52 Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000; 86 (5) 667-671
  • 53 Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sørensen HT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118 (19) 4768-4776
  • 54 Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005; 53 (6) 966-972
  • 55 Torti DC, Christensen BC, Storm CA , et al. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol 2011; 65 (2) 304-312
  • 56 Asgari MM, Chren MM, Warton EM, Friedman GD, White E. Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol 2010; 146 (4) 388-395
  • 57 Grau MV, Baron JA, Langholz B , et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 2006; 119 (3) 682-686
  • 58 Elmets CA, Viner JL, Pentland AP , et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102 (24) 1835-1844
  • 59 Ahmad N, Gilliam AC, Katiyar SK, O'Brien TG, Mukhtar H. A definitive role of ornithine decarboxylase in photocarcinogenesis. Am J Pathol 2001; 159 (3) 885-892
  • 60 Rebel H, van Steeg H, Beems RB, Schouten R, de Gruijl FR, Terleth C. Suppression of UV carcinogenesis by difluoromethylornithine in nucleotide excision repair-deficient Xpa knockout mice. Cancer Res 2002; 62 (5) 1338-1342
  • 61 Weeks CE, Herrmann AL, Nelson FR, Slaga TJ. alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci U S A 1982; 79 (19) 6028-6032
  • 62 Carbone PP, Pirsch JD, Thomas JP , et al. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol Biomarkers Prev 2001; 10 (6) 657-661
  • 63 Alberts DS, Dorr RT, Einspahr JG , et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000; 9 (12) 1281-1286
  • 64 Bailey HH, Kim K, Verma AK , et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of alpha-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila) 2010; 3 (1) 35-47
  • 65 Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther 2008; 8 (6) 829-838
  • 66 Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Xeroderma Pigmentosum Study Group. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Lancet 2001; 357 (9260) 926-929
  • 67 Black HS. Influence of dietary factors on actinically-induced skin cancer. Mutat Res 1998; 422 (1) 185-190
  • 68 Barthelman M, Chen W, Gensler HL, Huang C, Dong Z, Bowden GT. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998; 58 (4) 711-716
  • 69 Hakim IA, Harris RB, Ritenbaugh C. Citrus peel use is associated with reduced risk of squamous cell carcinoma of the skin. Nutr Cancer 2000; 37 (2) 161-168
  • 70 Stratton SP, Saboda KL, Myrdal PB , et al. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutr Cancer 2008; 60 (3) 325-330
  • 71 Stratton SP, Alberts DS, Einspahr JG , et al. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila) 2010; 3 (2) 160-169
  • 72 Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7 (9) 684-700
  • 73 Gandini S, Raimondi S, Gnagnarella P, Doré JF, Maisonneuve P, Testori A. Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 2009; 45 (4) 634-641
  • 74 Song F, Qureshi AA, Han J. Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer Res 2012; 72 (13) 3282-3289
  • 75 Prado R, Francis SO, Mason MN, Wing G, Gamble RG, Dellavalle R. Nonmelanoma skin cancer chemoprevention. Dermatol Surg 2011; 37 (11) 1566-1578
  • 76 Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318 (25) 1633-1637
  • 77 Tangrea JA, Edwards BK, Taylor PR , et al; Isotretinoin-Basal Cell Carcinoma Study Group. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J Natl Cancer Inst 1992; 84 (5) 328-332
  • 78 Bavinck JN, Tieben LM, Van der Woude FJ , et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13 (8) 1933-1938
  • 79 Levine N, Moon TE, Cartmel B , et al; Southwest Skin Cancer Prevention Study Group. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 1997; 6 (11) 957-961
  • 80 Moon TE, Levine N, Cartmel B , et al; Southwest Skin Cancer Prevention Study Group. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 1997; 6 (11) 949-956
  • 81 Gibson GE, O'Grady A, Kay EW, Murphy GM. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol 1998; 10 (1) 42-47
  • 82 McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999; 140 (4) 656-660
  • 83 George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43 (4) 269-273
  • 84 McNamara IR, Muir J, Galbraith AJ. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 2002; 21 (11) 1201-1205
  • 85 de Sévaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49 (3) 407-412
  • 86 Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49 (4) 644-650
  • 87 Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005; 141 (4) 456-464
  • 88 Kadakia KC, Barton DL, Loprinzi CL , et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer 2012; 118 (8) 2128-2137